Table 2.
Sensitivity and specificity of all test assays
| Test Assay |
Sensitivity day 2–7 |
Sensitivity day 8–18 |
Overall sensitivity day 2-d18 |
Specificity |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IgM* | IgG | IgM* + IgG | IgM* | IgG | IgM* + IgG | IgM* | IgG | IgM* + IgG | IgM* | IgG | |
| Point-of-care test | |||||||||||
| Corona Virus (COVID-19) Combined IgM/IgG Rapid test (Sol scientifics) | 57% | 14% | 57% | 94% | 88% | 94% | 83% | 65% | 83% | 79% | 100% |
| COVID-19 IgG/IgM Rapid test Cassette (Orient Gene) | 43% | 29% | 43% | 94% | 88% | 94% | 78% | 70% | 78% | 100% | 100% |
| SARS-CoV-2 Ab rapid test (Wantai) | n.a. | n.a. | 43% | n.a. | n.a. | 94% | n.a. | n.a. | 78% | n.a. | 100% |
| COVID-19 IgG/IgM RAPID TEST (PRIMA PROFESSIONAL) | 0% | 29% | 29% | 50% | 81% | 88% | 35% | 65% | 70% | 95% | 100% |
| Diagnostic Kit for IgG/IgM Antibody to SARS-CoV-2 (WIZ BIOTECH) | 14% | 14% | 14% | 94% | 94% | 94% | 70% | 70% | 70% | 95% | 100% |
| Enzyme-Linked Immunosorbent Assay (ELISA) | |||||||||||
| Anti-SARS-CoV-2 (EUROIMMUN)* | 57% | 29% | 57% | 94% | 88% | 94% | 83% | 70% | 83% | 95% | 100% |
| Novel Coronavirus COVID-19 (Epitope Diagnostics) | 29% | 71% | 71% | 69% | 94% | 94% | 57% | 87% | 87% | 95% | 89% |
| SARS-CoV-2 IgG ELISA Kit (Creative Diagnostics) | 29% | 14% | 29% | 94% | 88% | 94% | 74% | 65% | 74% | 100% | 100% |
| Human Anti-2019 nCoV(N) IgG ELISA kit (Finetest) | n.a. | 29% | n.a. | n.a. | 88% | n.a. | n.a. | 70% | n.a. | n.a. | 83% |
| Chemiluminescent microparticle immunoassay (CMIA) | |||||||||||
| SARS-CoV-2 IgG (Abbott) | n.a. | 29% | n.a. | n.a. | 88% | n.a. | n.a. | 70% | n.a. | n.a. | 100% |
| Chemiluminescence immunoassay (CLIA) | |||||||||||
| Liaison SARS-CoV-2 S1/S2 IgG (DiaSorin) | n.a. | 0% | n.a. | n.a. | 81% | n.a. | n.a. | 59% | n.a. | n.a. | 100% |
| Anti-SARS-CoV-2 (EUROIMMUN)*: IgA instead of IgM; n.a.: not applicable | |||||||||||